Research on Parkinson's disease and its treatment. Covers mitochondrial protection, genetic progression markers, antibody therapies, and disease costs.
Researchers found that Parkinson's disease dopamine neurons can shut down without fully dying, releasing chemicals that cause inflammation and senescence in healthy neighbors. This discovery suggests new avenues for therapies targeting SATB1 or p21 to prevent or slow the disease.
A review of case-control fecal gut microbiome studies in Parkinson's disease found varying results, but replicated findings include an increase in Verrucomicrobiaceae and Akkermansia. The researchers recommend integrating existing data to address confounders and propose future studies focus on biomarkers for PD diagnosis.
A Dutch study found that early onset of PD, memory and thinking impairment, and high levodopa medication use are linked to increased mortality. The study suggests that progressive motor impairment may be a key factor in the association between PD and reduced life expectancy.
Scientists propose that Parkinson's disease can be divided into two subtypes, with some cases starting in the gut and others in the brain. This hypothesis reconciles discrepant findings from neuropathological literature, suggesting a more complex understanding of the disorder's origins.
Scientists at the University of Dundee have created a method to permanently attach a small sugar molecule called O-GlcNAc to proteins in human cells. This allows them to investigate its role in neurological diseases such as Alzheimer's and Parkinson's, which are thought to be linked to O-GlcNAc disruption.
Researchers have identified a new enzyme that inhibits the LRRK2 pathway, which is responsible for most genetic cases of Parkinson's disease. The discovery provides hope for developing new treatments and suggests that the enzyme could benefit all individuals, regardless of whether they have Parkinson's or not.
A new three-year project aims to test the impact of sleep, exercise and low levels of alcohol on the glymphatic system, a recently discovered pathway that removes waste products from the brain. The study may lead to treatments that can target an important cause of both Parkinson's and Alzheimer's.
Researchers developed a novel approach to track tremor severity in Parkinson's patients, combining wearable sensors with machine-learning algorithms. The method accurately measures total and resting tremors throughout the day, even during free body movements.
The US Army has awarded Northeast Ohio Medical University (NEOMED) a $954,566 grant to study the impact of exercise on Parkinson's disease. The research aims to determine whether exercise can prevent or delay symptoms and provide a non-invasive therapeutic strategy for patients.
Researchers found gene therapy potential in treating neurological disorders like Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. New therapeutic approaches reprogram glial cells into motor neurons and deliver antibodies to protect against toxins.
A new strategy to treat Parkinson's disease has been developed by amplifying healthy GCase enzymes, alleviating symptoms in both human brain cells and mouse models. This approach may be relevant for multiple forms of PD with reduced activity of wild-type GCase.
A systematic review and meta-analysis of seven studies with 4.3 million participants found a potential association between bipolar disorder and an increased likelihood of a subsequent Parkinson disease diagnosis. However, subgroup analyses suggest possible overestimation of the magnitude of the associations.
A pioneering clinical trial will assess the safety and efficacy of cannabidiol (CBD) in alleviating hallucinations and delusions associated with Parkinson's-related psychosis. The study aims to determine whether CBD can correct abnormal brain functioning and improve quality of life for affected individuals.
A new study found that military veterans with post-traumatic stress disorder (PTSD) are more likely to experience a rare sleep disorder called REM sleep behavior disorder (RBD), which is also linked to an increased risk of developing neurodegenerative conditions like Parkinson's disease. Researchers hope that identifying patients with ...
Scientists observed how alpha-synuclein protein variants change over time, identifying initial stages of protein aggregates linked to early onset familial cases. They also found evidence of which protein species are important for amyloid filament growth and distinct structures depending on the mutation.
A team of researchers at the University of Pennsylvania is developing a critical tool for imaging the brains of patients with Parkinson's disease. They plan to use a special type of PET scan to detect the disease early on and provide detailed information about its progression.
Experts recommend promoting a 'brain-healthy lifestyle' through public education campaigns, research programs, and healthcare system preparedness. This can help reduce the risk of developing neurodegenerative diseases by emphasizing that healthy habits are generally good for brain health.
Researchers from Aarhus University discovered that Parkinson's patients have an immune imbalance in their blood, affecting the regulation of immune cells and anti-inflammatory molecules. This finding advocates for immune modulation as a potential alternative treatment for the disease.
Researchers identified genetic variants related to Parkinson's disease symptom onset, which could enable delimiting research on new therapeutic targets. The study, led by Cristina Malagelada, used biocomputing techniques and analyzed statistical interactions to identify genetic associations.
Researchers at Stanford University School of Medicine discovered a molecular defect that could lead to an accurate, early diagnosis of Parkinson's disease. They also identified a compound that reverses this defect in cells from patients and prevents neuronal death in animal models.
A Canadian team found that the LRRK2 gene is associated with an increased risk of Parkinson's disease, Crohn's disease, and leprosy due to enhanced inflammation. The study suggests that treating excessive inflammation may lead to new treatments and prevention strategies for these diseases.
Researchers at Neuroscience 2019 announce new gene therapy research promising to prevent, treat, and reverse incurable neurological disorders. Successes in restoring lost functions in animal models of neurological diseases are discussed, as well as technique advancements that may improve future treatments.
Researchers have found that a drug used to treat enlarged prostate may slow the progression of Parkinson's disease. Using big data and bench science, they discovered that terazosin can block cell death by activating an enzyme called PGK1, which is critical for cellular energy production.
A recent study by Radboud University Medical Center found that exercising at home using motivating apps significantly improves cardiovascular fitness and motor disability in Parkinson's patients. The cycling exercise program was more effective than stretching exercises alone, with a notable impact on disease progression.
Parkinson's disease is a neurodegenerative disorder characterized by motor and cognitive impairments. Scientists listed ways of applying genetic engineering to study and treat the disease, including manipulating mitochondria and iron homeostasis. CRISPR technology holds promise for finding new effective treatments.
The new guideline offers evidence-based recommendations to improve the standard of care for individuals with Parkinson's disease in Canada. It includes a new section on palliative care, highlighting the need to consider patients' quality of life throughout all phases of the disease.
Researchers at Hebrew University have developed an MRI technique that can detect molecular changes in the brain, allowing for early disease diagnosis and treatment. This non-invasive method provides biological readouts of brain tissue, enabling doctors to compare scans over time and differentiate between healthy and diseased tissue.
A study by Purdue University researchers suggests that urine analysis can provide faster diagnosis and treatment for traumatic brain injuries, which could lead to improved outcomes for soldiers and athletes. The test checks for elevated levels of acrolein in the urine within seven days of injury.
Researchers at Osaka University used X-ray imaging to visualize Lewy bodies in post-mortem brains and found α-synuclein aggregates with cross-β structure. This discovery supports the idea that Parkinson's disease is a systemic amyloidosis, with implications for diagnosis and treatment.
Researchers at Aarhus University have found evidence that Parkinson's disease may arise in the intestinal system, with harmful proteins like alpha-synuclein migrating to the brain and heart. This new study suggests that understanding how the disease starts could lead to more effective treatments.
Researchers at Vienna University of Technology have successfully incorporated individual metal atoms into a surface, enabling precise control over their chemical behavior. This breakthrough enables the creation of more efficient catalysts for environmentally friendly processes.
A novel study found that fatigue symptoms in Parkinson's Disease are associated with low diastolic blood pressure throughout the day. This association may lead to the development of new treatments targeting DBP without exacerbating cardiovascular effects.
Research published in JNeurosci suggests that estrogen may protect movement neurons from Parkinson's disease, with brain-selective estrogen treatment reducing alpha-synuclein breakdown and severe symptoms in male mice. Female mice also showed less severe symptoms at a later age, indicating potential benefits of estrogen-based treatments.
A new treatment could protect brain cells affected by Parkinson's disease, potentially slowing or stopping its progression. Dr Heather Mortiboys and her team will modify drug compounds that boost cell function in people living with Parkinson's.
Researchers have made a groundbreaking discovery about the alpha-synuclein protein's function in repairing DNA breaks, which may lead to new treatments for Parkinson's disease and other neurodegenerative disorders. The study reveals that alpha-synuclein plays a critical role in binding broken strands of DNA within the cell's nucleus.
Researchers developed neuro biomarkers to create 'smart' deep brain stimulators, adapting to Parkinson's disease patient needs. The technology responds to fluctuating symptoms in real-time, improving the therapy.
A molecule called GM1 ganglioside has been shown to inhibit the toxic effects of alpha-synuclein, a protein that forms clumps in Parkinson's disease. This discovery supports GM1 as a potential treatment for slowing disease progression and improving motor symptoms.
The Luxembourg Parkinson's Study aims to understand the disease mechanism and develop better treatments through a unique approach. By including 800 patients and a control group, researchers will monitor their progress annually to find new biomarkers and test personalized therapies.
Researchers at DZNE associate oxidative stress with the spreading of abnormal alpha-synuclein protein in Parkinson's disease, a neurodegenerative disorder. The findings suggest that oxidative stress may trigger the formation and aggregation of toxic alpha-synuclein species, leading to progressive pathology and neuronal damage.
Researchers discover that a gut infection can trigger symptoms of Parkinson's disease, suggesting an immune component to the disease. The study found that infection caused auto-immunity, leading to the killing of dopaminergic neurons.
A new study published in the European Journal of Neurology found that active sexual life is associated with reduced disability and improved quality of life in men with early Parkinson's disease. The analysis of 355 patients over two years suggests that exploring a patient's sexual life could be beneficial for their treatment.
A new study reveals that protein-linked sugars play a critical role in the uptake of alpha-synuclein proteins, which are associated with Parkinson's disease. The research identifies neurexin 1β as a key regulator in this process and suggests potential therapeutic targets for treating the disease.
Parkinson's UK is partnering with NRG Therapeutics to develop a potential drug that could safeguard dopamine cells and slow down the progression of Parkinson's. The partnership will support the identification of novel molecules to protect mitochondria within dopamine-producing cells.
Over a 40-year period, Antarctic sea ice coverage increased gradually until 2014 before declining sharply between 2014 and 2017. This trend is more pronounced than observed in the Arctic over the same time frame, with implications for climate modeling and understanding.
A team of researchers refutes the long-held common thesis that Parkinson's disease is caused by deposits of insoluble fibrils consisting of alpha-synculein. Instead, they found that Lewy bodies contain mainly membrane fragments, lipids, and other cellular material.
Researchers developed a mouse model that recapitulates Parkinson's disease's progression, showing how misfolded protein α-synuclein spreads from the gut to the brain. The study supports Braak's hypothesis and suggests potential therapeutic targets.
Researchers at Johns Hopkins Medicine found evidence that Parkinson's disease originates in the gut and travels up the brain's neurons. The study used mice with misfolded alpha-synuclein protein, which causes nerve cell death, to demonstrate the connection.
Researchers have found an enzyme in the body that metabolizes compounds from tobacco smoke, alcohol, and certain foods into chemicals that trigger Parkinson's disease. Mitochondrial CYP2D6 is a promising new target for treating idiopathic Parkinson's disease.
Researchers at King's College London have identified the earliest signs of Parkinson's disease in the brain, many years before symptoms appear. The study found changes to the serotonin system as a key early warning signal for the disease.
Researchers investigated mirror activity in healthy humans and found that amplitude grows with repetition, while latency decreases. This inverse relation may be linked to fatigue-induced inhibitory mechanisms failure.
Researchers developed a novel technique using transcranial ultrasound and microbubbles to open the blood-brain barrier, enabling drugs to penetrate the brain and restore dopaminergic pathways. The method has been approved by FDA for clinical trials in Alzheimer's patients and shows promise for treating Parkinson's disease at early stages.
Researchers have found that anle138b can reduce alpha-synuclein clumps, restore dopamine levels and stop the progression of Parkinson's. Early treatment may be crucial in stopping the condition in its tracks.
A research team from Osaka University has developed a novel gene therapy approach that targets α-synuclein, a protein associated with Parkinson's disease. By using amido-bridged nucleic acid-modified antisense oligonucleotides, the treatment effectively decreases α-synuclein production and reduces disease severity in mice models.
Researchers track early stages of alpha-synuclein protein aggregation in Parkinson's disease, which can lead to significant delay in disease progression. The study's novel method using super-resolution microscopy and advanced analysis has the potential to detect disease progression before symptoms appear.
The National Institutes of Health has awarded a $3 million grant to the Cleveland Clinic to conduct a multi-site clinical trial investigating the long-term effects of aerobic exercise on slowing Parkinson's disease progression. The CYCLE trial aims to determine if high-intensity aerobic exercise can slow disease advancement.
Parkinson's disease can spread throughout the brain via tiny channels, where harmful protein aggregates bind and 'hitch a lift' with channel-forming proteins. This process involves specific proteins called connexins, which create small channels between cells.
A national Taiwanese health database study found people with bipolar disorder were nearly seven times as likely to develop Parkinson's disease as those without the condition. The risk was higher for those hospitalized more frequently, developing the disease at a younger age.
Researchers discovered a novel noninvasive electrophysiological biomarker for Parkinson's disease using scalp electrodes and electroencephalography (EEG). The approach showed promise for developing wearable technology to monitor disease-related brain activity at home.
A study from the University of Oregon suggests that specific angles and sharpness of brain waves in unfiltered EEG data may indicate Parkinson's disease. Researchers used raw, unfiltered beta waves to distinguish between patients on and off medication, providing a potentially new approach for diagnosis and treatment.
Parkin's activity depends on recruitment and activation by proteins such as PINK1 and MITOL. The discovery of MITOL's role in tagging damaged mitochondria could lead to improved therapies for Parkinson's disease.